Eton Pharmaceuticals (ETON) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Eton Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $29.4M of ETON stock on the open market.
Get emailed when insiders cluster-buy stocks like ETON
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ETON insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $229K | 1 |
| Q3 2026 | — | 0 | $20.5M | 20 |
| Q2 2026 | — | 0 | $8.7M | 8 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Eton Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $29.4M. Among insiders with enough purchase history to measure, Opaleye Management Inc. (10% Owner) has the highest Insider Score at 99. 0 of 29 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | David KrempaChief Business Officer | Sell | 4,16643,381 held (−9%) | $55.07 | $229K | +0.3% | — |
| Aug 31SEC | Paul V MaierDirector | Sell | 36,38773,358 held (−33%) | $58.64 | $2.1M | -5.8% | — |
| Aug 31SEC | Paul V MaierDirector | Sell | 13,48559,873 held (−18%) | $60.21 | $812K | -8.3% | — |
| Aug 31SEC | Paul V MaierDirector | Sell | 12859,745 held (−0%) | $61.77 | $8K | -10.6% | — |
| Aug 28SEC | Paul V MaierDirector | Sell | 36,38773,358 held (−33%) | $58.64 | $2.1M | -5.8% | — |
| Aug 28SEC | Paul V MaierDirector | Sell | 13,48559,873 held (−18%) | $60.21 | $812K | -8.3% | — |
| Aug 28SEC | Paul V MaierDirector | Sell | 12859,745 held (−0%) | $61.77 | $8K | -10.6% | — |
| Aug 24SEC | David KrempaChief Business Officer | Sell | 25,00037,025 held (−40%) | $65.07 | $1.6M | -15.2% | — |
| Aug 20SEC | Sean BrynjelsenCEO, President | Sell | 47,3071,004,909 held (−4%) | $60.17 | $2.8M | -8.2% | — |
| Aug 20SEC | Sean BrynjelsenCEO, President | Sell | 36,373968,536 held (−4%) | $61.11 | $2.2M | -9.7% | — |
| Aug 20SEC | Sean BrynjelsenCEO, President | Sell | 8,9781,052,216 held (−1%) | $62.65 | $562K | -11.9% | — |
| Aug 20SEC | Sean BrynjelsenCEO, President | Sell | 7,342961,194 held (−1%) | $62.12 | $456K | -11.1% | — |
| Jul 17SEC | Opaleye Management Inc.10% Owner | Sell | 15,0002,665,000 held (−1%) | $37.54 | $563K | +47.1% | 99 |
| Jul 17SEC | Opaleye Management Inc.10% Owner | Sell | 13,31540,000 held (−25%) | $37.54 | $500K | +47.1% | 99 |
| Jul 16SEC | Opaleye Management Inc.10% Owner | Sell | 15,0002,665,000 held (−1%) | $37.54 | $563K | +47.1% | 99 |
| Jul 16SEC | Opaleye Management Inc.10% Owner | Sell | 13,31540,000 held (−25%) | $37.54 | $500K | +47.1% | 99 |
| Jul 7SEC | Opaleye Management Inc.10% Owner | Sell | 65,0002,710,000 held (−2%) | $37.39 | $2.4M | +47.7% | 99 |
| Jul 7SEC | Opaleye Management Inc.10% Owner | Sell | 25,00060,000 held (−29%) | $37.39 | $935K | +47.7% | 99 |
| Jul 7SEC | Opaleye Management Inc.10% Owner | Sell | 20,0002,680,000 held (−1%) | $38.37 | $767K | +43.9% | 99 |
| Jul 7SEC | Opaleye Management Inc.10% Owner | Sell | 10,0002,700,000 held (−0%) | $38.00 | $380K | +45.3% | 99 |
| Jul 7SEC | Opaleye Management Inc.10% Owner | Sell | 6,68553,315 held (−11%) | $38.37 | $257K | +43.9% | 99 |
| Jun 17SEC | Jennifer Mckie AdamsDirector | Sell | 50,000 | $32.48 | $1.6M | +70.0% | — |
| May 29SEC | Sean BrynjelsenCEO, President | Sell | 119,852833,842 held (−13%) | $31.88 | $3.8M | +73.2% | — |
| May 29SEC | Sean BrynjelsenCEO, President | Sell | 148833,694 held (−0%) | $32.67 | $5K | +69.0% | — |
| May 27SEC | David KrempaChief Business Officer | Sell | 37,52425,249 held (−60%) | $31.49 | $1.2M | +75.3% | — |
| May 27SEC | David KrempaChief Business Officer | Sell | 32,96335,083 held (−48%) | $33.22 | $1.1M | +66.2% | — |
| May 27SEC | David KrempaChief Business Officer | Sell | 19,67925,249 held (−44%) | $31.47 | $619K | +75.4% | — |
| May 27SEC | David KrempaChief Business Officer | Sell | 9,31525,768 held (−27%) | $33.88 | $316K | +63.0% | — |
| May 27SEC | David KrempaChief Business Officer | Sell | 51925,249 held (−2%) | $35.00 | $18K | +57.7% | — |
Insiders at Eton Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Sean BrynjelsenCEO, President | — | $9.9M | Aug 20, 2026 | — |
| Opaleye Management Inc.10% Owner | — | $6.9M | Jul 17, 2026 | 99 |
| Paul V MaierDirector | — | $5.9M | Aug 31, 2026 | — |
| David KrempaChief Business Officer | — | $5.1M | Oct 6, 2026 | — |
| Jennifer Mckie AdamsDirector | — | $1.6M | Jun 17, 2026 | — |
ETON stock: common questions
Are Eton Pharmaceuticals, Inc. insiders buying ETON stock?
In the past 12 months, 0 insiders reported open-market purchases of ETON worth $0.
Are Eton Pharmaceuticals, Inc. insiders selling ETON stock?
5 insiders reported sales worth $29.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ETON's 52-week range?
Over the past year ETON has traded between $14.35 and $64.43. It last closed at $55.21 on Oct 9, 2026.